期刊
ANNALS OF NEUROLOGY
卷 80, 期 3, 页码 401-411出版社
WILEY-BLACKWELL
DOI: 10.1002/ana.24725
关键词
-
资金
- NIH NINDS (National Institute of Neurological Disorders and Stroke) [NS 44233, U54 NS065736, K23NS075141]
- Mayo Center for Translational Science Activities [UL1 TR000135]
- Mayo funds
- NIH National Institute of Neurological Diseases and Stroke [U54 NS065736]
- NIH Office of Rare Diseases Research
ObjectiveTo systematically compare transthyretin with primary amyloid neuropathy to define their natural history and the underlying mechanisms for differences in phenotype and natural history. MethodsAll patients with defined amyloid subtype and peripheral neuropathy who completed autonomic testing and electromyography at Mayo Clinic Rochester between 1993 and 2013 were included. Medical records were reviewed for time of onset of defined clinical features. The degree of autonomic impairment was quantified using the composite autonomic severity scale. Comparisons were made between acquired and inherited forms of amyloidosis. ResultsOne hundred one cases of amyloidosis with peripheral neuropathy were identified, 60 primary and 41 transthyretin. Twenty transthyretin cases were found to have Val30Met mutations; 21 had other mutations. Compared to primary cases, transthyretin cases had longer survival, longer time to diagnosis, higher composite autonomic severity scale scores, greater reduction of upper limb nerve conduction study amplitudes, more frequent occurrence of weakness, and later non-neuronal systemic involvement. Four systemic markers (cardiac involvement by echocardiogram, weight loss>10 pounds, orthostatic intolerance, fatigue) in combination were highly predictive of poor survival in both groups. InterpretationThese findings suggest that transthyretin has earlier and greater predilection for neural involvement and more delayed systemic involvement. The degree and rate of systemic involvement is most closely related to prognosis. Ann Neurol 2016;80:401-411
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据